Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oculis

19.28
-0.2000-1.03%
Post-market: 19.280.00000.00%16:11 EDT
Volume:44.96K
Turnover:863.84K
Market Cap:983.93M
PE:-8.23
High:19.48
Open:19.22
Low:18.98
Close:19.48
Loading ...

Promising Clinical Results and Market Potential Drive Buy Rating for Oculis Holding

TIPRANKS
·
07 Jan

Oculis price target raised to $31 from $23 at BofA

TIPRANKS
·
07 Jan

Oculis Trial Shows Potential for Optical Neuroprotective Therapy

Exec Edge
·
07 Jan

Oculis Holding’s OCS-05 Shows Promising Results in Phase 2 Trial for Acute Optic Neuritis

TIPRANKS
·
07 Jan

Oculis Holding Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Jan

Oculis Holding’s OCS-05 Receives Buy Rating Amid Promising Clinical Data and Regulatory Advancements

TIPRANKS
·
07 Jan

Bank of America Securities Sticks to Their Buy Rating for Oculis Holding (OCS)

TIPRANKS
·
06 Jan

1 Super Growth Stock Down 63% to Buy Hand Over Fist in 2025

Motley Fool
·
06 Jan

BUZZ-Oculis climbs on positive mid-stage trial for eye treatment

Reuters
·
06 Jan

Oculis Holding Says Phase 2 Trial of Acute Optic Neuritis Therapy Met Primary Safety Endpoint

MT Newswires Live
·
06 Jan

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

GlobeNewswire
·
06 Jan

Oculis Publishes Notification of Major Changes in Voting Rights

GlobeNewswire
·
04 Jan

Oculis Holding (OCS): A Biopharma Opportunity for Adventurous Investors

TIPRANKS
·
26 Dec 2024

TransMedics Stock Plunges 57.5% in Three Months: What's Next?

Zacks
·
14 Dec 2024

2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid

Motley Fool
·
11 Dec 2024

TransMedics Group, Inc. (TMDX): A Bull Case Theory

Insider Monkey
·
10 Dec 2024